IRIS
GAGLIARDINI, ROBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.080
NA - Nord America 1.620
AS - Asia 1.021
SA - Sud America 134
AF - Africa 83
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.574
RU - Federazione Russa 446
IT - Italia 438
SG - Singapore 369
GB - Regno Unito 318
IE - Irlanda 230
CN - Cina 229
DE - Germania 184
VN - Vietnam 161
BR - Brasile 115
SE - Svezia 113
FR - Francia 107
FI - Finlandia 69
HK - Hong Kong 67
IN - India 47
NL - Olanda 41
ZA - Sudafrica 40
UA - Ucraina 38
KR - Corea 31
CA - Canada 26
ES - Italia 24
BE - Belgio 20
TR - Turchia 20
AT - Austria 16
BD - Bangladesh 13
IQ - Iraq 11
JP - Giappone 10
MX - Messico 10
PK - Pakistan 10
UG - Uganda 10
PL - Polonia 9
AR - Argentina 8
ID - Indonesia 8
PT - Portogallo 7
ET - Etiopia 6
MA - Marocco 6
NG - Nigeria 6
KE - Kenya 5
MY - Malesia 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
JO - Giordania 4
LT - Lituania 4
CL - Cile 3
CO - Colombia 3
CR - Costa Rica 3
LB - Libano 3
NP - Nepal 3
SA - Arabia Saudita 3
TN - Tunisia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
EG - Egitto 2
EU - Europa 2
IR - Iran 2
LV - Lettonia 2
PA - Panama 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
BW - Botswana 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IL - Israele 1
IM - Isola di Man 1
JM - Giamaica 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PE - Perù 1
PS - Palestinian Territory 1
QA - Qatar 1
SI - Slovenia 1
TH - Thailandia 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 4.945
Salva come PNG Salva come JPEG
Città #
Southend 266
Singapore 248
Dublin 218
Dallas 207
Moscow 144
Ashburn 135
Munich 123
Chandler 113
Santa Clara 105
Fairfield 96
San Jose 85
Beijing 74
Hong Kong 64
Dong Ket 56
Ann Arbor 52
Helsinki 52
Siena 44
New York 40
Woodbridge 40
Milan 38
Hefei 34
Ho Chi Minh City 34
Los Angeles 34
Seattle 34
Princeton 33
Jacksonville 32
Lauterbourg 32
Seoul 31
Houston 29
Menlo Park 29
Wilmington 28
Johannesburg 27
Rome 27
Council Bluffs 26
Hanoi 24
Cambridge 21
Málaga 19
The Dalles 17
Brussels 15
Chennai 15
Buffalo 14
London 14
Shanghai 14
Dearborn 13
Boardman 12
Düsseldorf 12
Frankfurt am Main 12
San Mateo 12
São Paulo 12
Turku 12
Vienna 11
Florence 10
Nanjing 10
Nuremberg 10
Tokyo 10
Portsmouth 9
Kampala 8
Montreal 8
Perugia 8
Redondo Beach 8
Bengaluru 7
Da Nang 7
Warsaw 7
Washington 7
Addis Ababa 6
Amsterdam 6
Castel Volturno 6
Fremont 6
Naples 6
Orem 6
San Francisco 6
Toronto 6
Abuja 5
Atlanta 5
Chicago 5
Guangzhou 5
Spring 5
Amman 4
Belo Horizonte 4
Bologna 4
Brooklyn 4
Cagliari 4
Columbus 4
Deiva Marina 4
Denver 4
Erbil 4
Grosseto 4
Izmir 4
Jyväskylä 4
Padua 4
Rio de Janeiro 4
San Diego 4
Stockholm 4
Treviso 4
Akyurt 3
Americana 3
Ankara 3
Basingstoke 3
Boston 3
Bắc Ninh 3
Totale 3.147
Salva come PNG Salva come JPEG
Nome #
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 560
UTILIZZO DI MILTEFOSINA IN PAZIENTE CON LEISHMANIOSI MUCOSA ED INFEZIONE DA HIV 522
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 285
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 275
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 257
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 244
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 231
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 230
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 211
Use of Miltefosine in a Patient With Mucosal Leishmaniasis and HIV-coinfection: A Challenge in Long-Term Management 208
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 204
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 187
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 174
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects 155
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 150
Endocardite o non endocardite? Questo è il dilemma. 148
Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry 139
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 128
Efficacia viro-immunologica dei regimi antiretrovirali duplici e triplici contenenti dolutegravir: risultati di uno studio di coorte 127
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 118
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort 108
Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse 108
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study 93
Sexually transmitted infections in people with multidrug-resistant HIV 93
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors 79
Totale 5.034
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.840
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.840
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021127 0 0 0 0 0 0 0 0 0 36 13 78
2021/2022300 11 31 16 23 17 13 19 18 34 20 30 68
2022/2023421 26 51 65 41 25 76 15 32 33 28 15 14
2023/2024435 12 8 38 28 20 114 125 16 2 15 29 28
2024/20251.063 19 31 81 33 136 105 108 82 121 46 108 193
2025/20261.951 185 211 188 311 492 76 238 71 61 118 0 0
Totale 5.034